AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00131235
Drug: Sulfadoxine-pyrimethamine at 4-week intervals
RxNorm normalized name: Fansidar 500/25 (sulfadoxine / pyrimethamine) Oral Tablet
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
Trial: NCT03108131
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03108131
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01123785
Drug: INO-8875
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: eye drops for 14 days in one eye
Trial: NCT02680795
Drug: Belinostat IV
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.
Trial: NCT00892398
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
Trial: NCT00193531
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04459663
Drug: Toripalimab injection combine with Axitinib
RxNorm normalized name: toripalimab Injection
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in the group will be infused intravenously with fixed dose of 240mg JS001 on the first day of each cycle. Oral Axitinib 5mg bid (recommended interval of about 12 hours) was given daily from the second day of the initial cycle
Trial: NCT00193531
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00193531
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02861573
Drug: Olaparib 400 mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eight 50-mg capsules PO BID
Trial: NCT02861573
Drug: Docetaxel 75 mg/m^2
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Q3W
Trial: NCT02861573
Drug: Prednisone 5 mg
RxNorm normalized name: prednisone 5 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 5-mg tablet PO BID
Trial: NCT02861573
Drug: Enzalutamide 160 mg
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
Trial: NCT02861573
Drug: Olaparib 300 mg
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Two 150-mg tablets PO BID
Trial: NCT02861573
Drug: Abiraterone acetate 1000 mg
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Two 500-mg or four 250-mg tablets PO QD
Trial: NCT02861573
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mg PO QD
Trial: NCT02861573
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Q3W
Trial: NCT02861573
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV on Days 1, 2 and 3 of each cycle
Trial: NCT04021108
Drug: Nivolumab 240 MG
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
Trial: NCT03839498
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered.
Trial: NCT03961464
Drug: d-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT01922050
Drug: LEO 43204 Formulation 1 Dose X
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02640573
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
Trial: NCT03876574
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intra-arterially for 30 minutes
Trial: NCT03876574
Drug: Floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intra-arterially continuously for 14 days
Trial: NCT03876574
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intra-arterially continuously with 5-FUDR
Trial: NCT00331422
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
Trial: NCT00331422
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
Trial: NCT03633708
Drug: Etelcalcetide
RxNorm normalized name: Etelcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
Trial: NCT03789240
Drug: Copanlisib
RxNorm normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
Trial: NCT02805972
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg / 0.1 ml
Trial: NCT03099356
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus 4 mg, PO, days 1-28
Trial: NCT03211871
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
Trial: NCT00539591
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given either IV or SQ. Therapeutic drug class: interferon.
Trial: NCT00539591
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO. Therapeutic drug class: antineoplastic agent.
Trial: NCT02127047
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03496870
Drug: Opicapone
RxNorm normalized name: opicapone
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: catechol-O-methyltransferase (COMT) inhibitor
Trial: NCT00539591
Drug: Recombinant interferon alfa-2b
RxNorm normalized name: Interferon alfa-2b, recombinant
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
Trial: NCT04362254
Drug: Spesolimab
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spesolimab
Trial: NCT04005690
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04005690
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04005690
Drug: Onvansertib
RxNorm normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04005690
Drug: Azenosertib
RxNorm normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04005690
Drug: Saruparib
RxNorm normalized name: Saruparib
DrugBank: Saruparib (DB18982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04529148
Drug: Ginkgo biloba dropping pills，best western medicine treatment
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04529148
Drug: Mimetic drug of ginkgo biloba dropping pills，best western medicine treatment
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04568434
Drug: Olezarsen
RxNorm normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olezarsen was administered by SC injection.
Trial: NCT03905798
Drug: Lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses.
Trial: NCT00759148
Drug: Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eye drops
Trial: NCT01133821
Drug: IPSRT plus quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)
Trial: NCT04356742
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg, orally, once daily, up to 24weeks
Trial: NCT04356742
Drug: Evogliptin 5mg
RxNorm normalized name: alogliptin 12.5 MG
DrugBank: Evogliptin (DB12625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evogliptin 5mg, orally, once daily for background therapy
Trial: NCT01624129
Drug: Fluticasone
RxNorm normalized name: Fluticasone
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
Trial: NCT00861783
Drug: irinotecan and ON 01910.Na
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling.
Trial: NCT00861783
Drug: oxaliplatin and ON 01910.Na
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling.
Trial: NCT04356742
Drug: Metformin≥1000mg
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin≥1000mg, orally, daily for background therapy
Trial: NCT01387282
Drug: Anamorelin HCl
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
Trial: NCT04522908
Drug: Cabozantinib Oral Tablet
RxNorm normalized name: cabozantinib Oral Tablet
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib starting dose of 40 mg, oral, once daily for 4 weeks followed by Cabozantinib escalated dose of 60 mg, oral, once daily from week 5 onwards
Trial: NCT03370276
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
Trial: NCT03370276
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab intravenously (IV) at 500 mg/m\^2 or 250 mg/m\^2 as outlined in the treatment arms.
Trial: NCT02270814
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02270814
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02270814
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00311818
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01368003
Drug: STA9090 with Dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dutasteride 3.5 mg orally per day STA9090 200 mg/m\^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
Trial: NCT03815474
Drug: anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
Trial: NCT01927627
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution, single dose, fasted
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release Tablet, single dose, fasted
Trial: NCT03265470
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release Tablet (short duration, MR1), single dose, fasted
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release Tablet (long duration, MR2), single dose, fasted
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release Tablet (short duration, MR1), single dose, fed
Trial: NCT01706796
Drug: PF-06273340
RxNorm normalized name: PF-06273340
DrugBank: PF-06273340 (DB12269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Release Tablet (long duration, MR2), single dose, fed
Trial: NCT02744703
Drug: CAPE-T
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental group
Trial: NCT02744703
Drug: CAPE-S
RxNorm normalized name: S-2
DrugBank: Racepinephrine (DB11124)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental group
Trial: NCT03673826
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 9 cycles 20/36mg/m2 days 1,2,8,9,15,16
Trial: NCT03673826
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
Trial: NCT03673826
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
Trial: NCT03997448
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg IV
Trial: NCT03997448
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Abemiciclib 150mg PO
Trial: NCT00406757
Drug: Nelarabine injection 400mg/m2
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.
Trial: NCT00406757
Drug: Nelarabine injection 650mg/m2
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Trial: NCT00406757
Drug: Nelarabine injection 1000mg/m2
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Trial: NCT00406757
Drug: Nelarabine injection 1500mg/m2
DrugBank: Nelarabine (DB01280)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Trial: NCT00961649
Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00961649
Drug: Brinzolamide ophthalmic suspension, 1%
DrugBank: Brinzolamide (DB01194)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00961649
Drug: Brimonidine tartrate ophthalmic solution, 0.2%
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes